Although the phenomenon of sundowning has been referred to in the literature for over 60 years, research findings vary dramatically. For instance, rates are estimated to range from 2.4 to 66 percent. Higher rates are reported by caregivers of non-institutionalized dementia patients. Theories to explain sundowning are also varied and include:
- maladaptive response to fatigue
- disordered circadian rhythm, possibly from damage to the suprachiasmatic nucleus of the brain's hypothalamus
- diminished natural light coupled with dementia-associated sensory and cognitive impairments especially visual impairment (agnosia), that limit the ability to decipher what is in the environment
- reactive distress and anxiety regarding people who appear strange
- decreased environmental stimulation and caregiver availability
- increased pain or discomfort (i.e. from arthritis, constipation, etc.)
Treatments
• caregiver reassurance
• scheduling activities around the time when sundowning occurs
• providing adequate light
• minimizing unnecessary or agitating noise (i.e. banging of dishes, loud conversations)
• light therapy (although research reviews do not support its effectiveness)
These are easy measures to initiate and might diminish agitation the time of the usual agitation.
Music Therapy
Studies have shown that daily music therapy, listening to either preferred music or classical music chosen by caregivers, reduces stress and agitation in patients with dementia.
Melatonin
Several dementia studies have shown that melatonin improves sleep quality and reduces sundowning behavior and night-time wandering. One study found no effect on insomnia in nursing home residents.
Melatonin may also help to prevent or treat delirium. In one study, melatonin was started at a dose of 2 mg at 8:00 p.m. for sundowning and sleep disorder in a dementia patient who also had symptoms of delirium, including agitation and aggression. Sleep improved with a week, and significant behavioural improvement was also noted within 2 hours of taking melatonin. A therapeutic trial with an additional dose of 2 mg given at 3:00 p.m. was started, and the patient’s symptoms gradually improved over the subsequent 2 weeks. A follow-up at 2 months showed no recurrence of symptoms of delirium.
More study is needed to assess this promising treatment.
Pharmacological Treatments
Studies show that antipsychotics are the most widely used "off label" treatment for sundowning and other dementia-related behavioural disturbances. Risperidone (one of a newer class of medications referred to as atypical antipsychotics) has been shown to reduce aggressiveness, wandering, and sleep with less severe side-effects than first generation antipsychotics. Although off label use of risperidone is common, it has only been specifically approved for use with dementia patients with severe aggression and/or psychosis who pose a risk to themselves and others.
Side-effects may include sleepiness, agitation, anxiety, headache, trembling, excessive saliva, stiffness, leg restlessness, dizziness, fast heart rate, increased weight gain and risk of diabetes, apathy, and emotional withdrawal. Although atypical antipsychotics are less prone than other antipsychotics to cause severe side-effects such as muscle twitching and Parkinson’s disease-like movement problems, such symptoms can still occur. Not everyone who takes risperidone will experience side-effects.
Risperidone and other antipsychotics have significant safety risks, and have been shown to increase the risk of death. Extreme caution should be used in prescribing neuroleptic drugs for patients with vascular dementia due to significantly increased risk of stroke. Despite warnings issued by Health Canada, the use of risperidone and other antipsychotics for the behavioral management of dementia patients continues to soar, particularly in long-term care where dementia patients are likely to experience increased behavioural challenges and where resources to manage those challenges are limited (see The Star article).
The class of drugs called hypnotics (i.e. bendodiazepines) are not considered appropriate for use with dementia patients. Although the use of such drugs may decrease wandering, they have also been shown to increase confusion, agitation and risk of falls.
Donepzil (Aricept) is the most widely used AChIs drug therapy to slow the process of decline in patients with mild to moderate symptoms of Alzheimer's disease. Other AChIs include rivastigmine (Exelon) and glantamine (Reminyl).
Between 40 and 70 per cent of people with Alzheimer's disease may experience some benefit from these drugs, with symptoms showing improvement temporarily (for between six and 12 months in most cases) and then gradually worsening over the following months. Compared to placebo, benefits are small but significant, and may include: reduced anxiety, improvements in cognition, motivation, memory and concentration, and ability to continue daily activities (eg personal care, shopping, dressing).
Similar benefits have been reported for vascular dementia patients, but not in activities of daily living. It is not clear whether these drugs also have benefits for behavioural changes such as sundowning, agitation and aggression. Trials in this area have yielded mixed results.
References
Bruser, D., McLean, J., & Bailey, A. (2014, April 15). Use of antipsychotics soaring at Ontario nursing homes. The Star. Retrieved from https://www.thestar.com/news/canada/2014/04/15/use_of_antipsychotics_soaring_at_ontario_nursing_homes.html
Goga, J. K. (2014). Dignifying dementia: Accepting the limitations of medications. Mental Health Clinician 4(4), 162-163.
Jonghe, A., Munster, B. C., & Rooij, S. E. (2014). Effectiveness of Melatonin for Sundown Syndrome and Delirium. Journal of The American Geriatrics Society, 62(2), 412. doi:10.1111/jgs.12671
Khachiyants, N., Trinkle, D., Son, S. J., & Kim, K. Y. (2011). Sundown syndrome in persons with dementia: an update. Psychiatry Investigation, 8(4), 275-287. doi:10.4306/pi.2011.8.4.275
Lammers, M., & Ahmed, A. I. (2013). Melatonin for Sundown Syndrome and Delirium in Dementia: Is It Effective? Journal of the American Geriatrics Society, 61(6), 1045-1046. doi:10.1111/jgs.12296
Zare, M., Ebrahimi, A. A., & Birashk, B. (2010). The effects of music therapy on reducing agitation in patients with Alzheimer's disease, a pre-post study. International Journal of Geriatric Psychiatry, 25(12), 1309-1310. doi:10.1002/gps.2450
Additional Information
Iowa Geriatric Education Center https://www.healthcare.uiowa.edu/IGEC/IAAdapt/
National Nursing Home Quality Improvement Campaign https://nhqualitycampaign.org/